Loading organizations...

§ Private Profile · Oss, Noord-Brabant, The Netherlands
Biotech company developing therapeutic antibodies for immune-mediated inflammatory diseases, targeting Neutrophil Extracellular Traps.
Citryll is an Oss, The Netherlands-based biotechnology company developing therapeutic antibodies that target Neutrophil Extracellular Traps to treat immune-mediated inflammatory diseases. The company's lead clinical candidate, CIT-013, utilizes a dual mechanism to inhibit the formation and enhance the clearance of these traps, addressing the source of inflammation for conditions like rheumatoid arthritis and hidradenitis suppurativa. Citryll has secured significant capital to advance its clinical pipeline, highlighted by a EUR 85 million Series B financing round completed in December 2024, which followed a previous EUR 18.5 million fundraise. This venture-backed enterprise is supported by prominent institutional investors, including Forbion, Novartis Venture Fund, and JJDC. The organization is currently led by CEO Helmuth van Es and CMO Maarten Kraan as it prepares for Phase 2a clinical trials. The founding year and original founders are not publicly disclosed.
Citryll has raised $127.9M across 3 funding rounds.
Citryll has raised $127.9M in total across 3 funding rounds.
Citryll is a Netherlands‑based biotech developing a first‑in‑class monoclonal antibody (CIT‑013) that targets Neutrophil Extracellular Traps (NETs) to treat immune‑mediated inflammatory diseases such as rheumatoid arthritis and hidradenitis suppurativa, and has progressed from Phase‑1 into planned Phase‑2 studies following multiple financing rounds including a €85M Series B in December 2024.[5][2]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Pharma Landscape
Quick Take & Future Outlook
Quick takeaway: Citryll is a well‑financed Dutch biotech focused on translating NET biology into a potential new class of anti‑inflammatory therapeutics via CIT‑013; upcoming Phase‑2 programs and translational data (including activity against EETs) will determine whether NET targeting becomes a broadly adopted therapeutic strategy.[2][6]
Citryll has raised $127.9M across 3 funding rounds. Most recently, it raised $90.0M Series B in December 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2024 | $90M Series B | Forbion, Novartis | Action Potential Venture Capital, Edward VAN Wezel, BGV (biogeneration Ventures), Energy Impact Partners, JAY, Novartis Venture Fund, Queensbridge Venture Partners, RA Capital, Seventure Partners, MO EL Bibany, TIM Ferriss | Announced |
| Jul 1, 2020 | $21M Series B | BGV (biogeneration Ventures), Seventure Partners | Action Potential Venture Capital, Energy Impact Partners, JAY, Queensbridge Venture Partners, RA Capital, MO EL Bibany, TIM Ferriss | Announced |
| Jul 3, 2019 | $16.9M Venture Round | — | — | Announced |
Citryll has raised $127.9M in total across 3 funding rounds.
Citryll's investors include Forbion, Novartis, Action Potential Venture Capital, Edward Van Wezel, BGV (BioGeneration Ventures), Energy Impact Partners, Jay, Novartis Venture Fund, QueensBridge Venture Partners, RA Capital, Seventure Partners, Mo El-Bibany.